Pramod N Nehete

List of Publications by Year
in descending order

74 papers	1,288 citations	304743 22 h-index	414414 32 g-index
83 all docs	83 docs citations	83 times ranked	1456 citing authors

#	Article	IF	Citations
1	Extending Drug Release from Implants via Transcutaneous Refilling with Solid Therapeutics. Advanced Therapeutics, 2022, 5, .	3.2	7
2	Effects of relocation on immunological and physiological measures in female squirrel monkeys (Saimiri boliviensis boliviensis). PLoS ONE, 2021, 16, e0240705.	2.5	3
3	Innate immunity stimulation via CpG oligodeoxynucleotides ameliorates Alzheimerâ€™s disease pathology in aged squirrel monkeys. Brain, 2021, 144, 2146-2165.	7.6	19
4	Ultra-long acting prodrug of dolutegravir and delivery system â€“ Physicochemical, pharmacokinetic and formulation characterizations. International Journal of Pharmaceutics, 2021, 607, 120889.	5.2	12
5	Preventive Efficacy of a Tenofovir Alafenamide Fumarate Nanofluidic Implant in SHIVâ€Challenged Nonhuman Primates. Advanced Therapeutics, 2021, 4, 2000163.	3.2	28
6	Short-Term Relocation Stress-Induced Hematological and Immunological Changes in Saimiri boliviensis boliviensis. Journal of Immunology Research, 2021, 2021, 1-12.	2.2	3
7	Evaluation of class C CpG ODN efficacy and safety profile in a squirrel monkey model of AD pathology. Alzheimer's and Dementia, 2021, 17, .	0.8	0
8	MRI longitudinal and crossâ€sectional monitoring of amyloid pathology in nonâ€human primates. Alzheimer's and Dementia, 2021, 17, .	0.8	0
9	Comparative Analysis of Cellular Immune Responses in Conventional and SPF Olive Baboons (<i>Papio) Tj ETQq1 1 0.784314 rgBT /Ov	1.0	3
10	Viral load Reduction in SHIV-Positive Nonhuman Primates via Long-Acting Subcutaneous Tenofovir Alafenamide Fumarate Release from a Nanofluidic Implant. Pharmaceutics, 2020, 12, 981.	4.5	13
11	Enhanced In Vivo Vascularization of 3Dâ€Printed Cell Encapsulation Device Using Plateletâ€Rich Plasma and Mesenchymal Stem Cells. Advanced Healthcare Materials, 2020, 9, e2000670.	7.6	17
12	Neuroimaging of amyloid pathology in a nonâ€human primate model of sporadic CAA. Alzheimer's and Dementia, 2020, 16, e045327.	0.8	0
13	Evaluation of class C CpG ODN immunomodulatory potential in a nonâ€human primate model of sporadic CAA. Alzheimer's and Dementia, 2020, 16, e045330.	0.8	0
14	Class C CpG Oligodeoxynucleotide Immunomodulatory Response in Aged Squirrel Monkey (Saimiri) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	3.4	12
15	Trans-urocanic acid enhances tenofovir alafenamide stability for long-acting HIV applications. International Journal of Pharmaceutics, 2020, 587, 119623.	5.2	10
16	Lymphocytes upregulate CD36 in adipose tissue and liver. Adipocyte, 2019, 8, 154-163.	2.8	15
17	Divergent HIV-1-Directed Immune Responses Generated by Systemic and Mucosal Immunization with Replicating Single-Cycle Adenoviruses in Rhesus Macaques. Journal of Virology, 2019, 93, .	3.4	11
18	Effects of Transportation and Relocation on Immunologic Measures in Cynomolgus Macaques (Macaca fascicularis). Journal of the American Association for Laboratory Animal Science, 2019, 58, 774-782.	1.2	9

#	Article	IF	Citations
19	Adipocytes impair efficacy of antiretroviral therapy. Antiviral Research, 2018, 154, 140-148.	4.1	44
20	P1â€100: INNATE IMMUNITY STIMULATION VIA CLASS C CPG ODN AND MRI MONITORING OF EFFICACY AND SAFETY IN AN AGED NONâ€HUMAN PRIMATE MODEL OF CAA. Alzheimer's and Dementia, 2018, 14, P309.	0.8	0
21	Cellular immune responses in peripheral blood lymphocytes of Giardia infected squirrel monkey (Saimiri boliviensis boliviensis) treated with Fenbendazole. PLoS ONE, 2018, 13, e0198497.	2.5	9
22	Transcutaneously refillable nanofluidic implant achieves sustained level of tenofovir diphosphate for HIV pre-exposure prophylaxis. Journal of Controlled Release, 2018, 286, 315-325.	9.9	66
23	Translational Model of Zika Virus Disease in Baboons. Journal of Virology, 2018, 92, .	3.4	25
24	Experimental Zika Virus Infection of Neotropical Primates. American Journal of Tropical Medicine and Hygiene, 2018, 98, 173-177.	1.4	38
25	[P3â€“053]: CEREBRAL AMYLOID ANGIOPATHY TREATMENT VIA INNATE IMMUNITY STIMULATION IN AGED NONâ€HUMAN PRIMATES. Alzheimer's and Dementia, 2017, 13, P950.	0.8	0
26	Effects of transportation, relocation, and acclimation on phenotypes and functional characteristics of peripheral blood lymphocytes in rhesus monkeys (Macaca mulatta). PLoS ONE, 2017, 12, e0188694.	2.5	20
27	Minimally invasive monitoring of CD4 T cells at multiple mucosal tissues after intranasal vaccination in rhesus macaques. PLoS ONE, 2017, 12, e0188807.	2.5	3
28	Phenotypic and Functional Characterization of Peripheral Blood Lymphocytes from Various Age- and Sex-Specific Groups of Owl Monkeys (). Comparative Medicine, 2017, 67, 67-78.	1.0	12
29	Age- and Sex-associated Differences in Phenotypic and Functional Characteristics of Peripheral Blood Lymphocytes in Chimpanzees (). Journal of the American Association for Laboratory Animal Science, 2017, 56, 509-519.	1.2	7
30	Age- and Sex-associated Differences in Phenotypic and Functional Characteristics of Peripheral Blood Lymphocytes in Chimpanzees (Pan troglodytes). Journal of the American Association for Laboratory Animal Science, 2017, , .	1.2	2
31	P4-018: Innate Immunity Stimulation Via Toll-Like Receptor 9 as a Novel Therapeutic Approach in Alzheimerâ€™s Disease. , 2016, 12, P1021-P1022.		3
32	Infectious SIV resides in adipose tissue and induces metabolic defects in chronically infected rhesus macaques. Retrovirology, 2016, 13, 30.	2.0	46
33	P2-323: Toll-like receptor 9 stimulation via CpG ODN in a non-human primate model of sporadic cerebral amyloid angiopathy. , 2015, 11, P618-P618.		3
34	Enhancement of Mucosal Immunogenicity of Viral Vectored Vaccines by the NKT Cell Agonist Alpha-Galactosylceramide as Adjuvant. Vaccines, 2014, 2, 686-706.	4.4	20
35	Obesity Related Alterations in Plasma Cytokines and Metabolic Hormones in Chimpanzees. International Journal of Inflammation, 2014, 2014, 1-11.	1.5	24
36	P3-415: TESTING OF INNATE IMMUNITY STIMULATION VIA TLR9 ON CEREBRAL AMYLOID ANGIOPATHY USING NON-HUMAN PRIMATES. , 2014, 10, P782-P782.		0

#	Article	IF	Citations
37	Procedures for Mucosal Immunization and Analyses of Cellular Immune Response to Candidate HIV Vaccines in Murine and Nonhuman Primate Models. Methods in Molecular Biology, 2014, 1184, 417-455.	0.9	4
38	Nerium oleander derived cardiac glycoside oleandrin is a novel inhibitor of HIV infectivity. FÃ¬toterapÃ¬Ã¢, 2013, 84, 32-39.	2.2	42
39	Phenotypic and Functional Characterization of Lymphocytes from Different Age Groups of Bolivian Squirrel Monkeys (Saimiri boliviensis boliviensis). PLoS ONE, 2013, 8, e79836.	2.5	17
40	Comparison of Systemic and Mucosal Immunization with Helper-Dependent Adenoviruses for Vaccination against Mucosal Challenge with SHIV. PLoS ONE, 2013, 8, e67574.	2.5	22
41	Lessons on Non-Progression of HIV Disease from Monkeys. Frontiers in Immunology, 2013, 4, 64.	4.8	3
42	Physiological and welfare consequences of transport, relocation, and acclimatization of chimpanzees (Pan troglodytes). Applied Animal Behaviour Science, 2012, 137, 183-193.	1.9	33
43	Functional Impairment of Central Memory CD4 T Cells Is a Potential Early Prognostic Marker for Changing Viral Load in SHIV-Infected Rhesus Macaques. PLoS ONE, 2011, 6, e19607.	2.5	12
44	Prime-Boost Vaccination Using Chemokine-Fused gp120 DNA and HIV Envelope Peptides Activates Both Immediate and Long-Term Memory Cellular Responses in Rhesus Macaques. Journal of Biomedicine and Biotechnology, 2010, 2010, 1-7.	3.0	6
45	Protection against Mucosal SHIV Challenge by Peptide and Helper-Dependent Adenovirus Vaccines. Viruses, 2009, 1, 920-938.	3.3	26
46	Alpha-galactosylceramide is an effective mucosal adjuvant for repeated intranasal or oral delivery of HIV peptide antigens. Vaccine, 2009, 27, 3335-3341.	3.8	67
47	Comparison of Replication-Competent, First Generation, and Helper-Dependent Adenoviral Vaccines. PLoS ONE, 2009, 4, e5059.	2.5	61
48	Selective induction of cell-mediated immunity and protection of rhesus macaques from chronic SHIVKU2 infection by prophylactic vaccination with a conserved HIV-1 envelope peptide-cocktail. Virology, 2008, 370, 130-141.	2.4	14
49	Intranasal immunization with synthetic peptides corresponding to the E6 and E7 oncoproteins of human papillomavirus type 16 induces systemic and mucosal cellular immune responses and tumor protection. Vaccine, 2007, 25, 3302-3310.	3.8	40
50	Oral immunization of rhesus macaques with adenoviral HIV vaccines using enteric-coated capsules. Vaccine, 2007, 25, 8687-8701.	3.8	52
51	Critical role of Arg59 in the high-affinity gp120-binding region of CD4 for human immunodeficiency virus type 1 infection. Virology, 2007, 363, 69-78.	2.4	8
52	Improving the Sensitivity of the ELISPOT Analyses of Antigen-Specific Cellular Immune Responses in Rhesus Macaques. , 2005, 302, 153-166.		2
53	Protection by dendritic cells-based HIV synthetic peptide cocktail vaccine: preclinical studies in the SHIV-rhesus model. Vaccine, 2005, 23, 2154-2159.	3.8	26
54	SHIV transmission and susceptibility to re-exposure through social contact following vaccination with an HIV synthetic peptide-cocktail: a case study. Journal of Medical Primatology, 2004, 33, 10-15.	0.6	3

#	Article	IF	Citations
55	A two-codon mutant of cholera toxin lacking ADP-ribosylating activity functions as an effective adjuvant for eliciting mucosal and systemic cellular immune responses to peptide antigens. Vaccine, 2004, 23, 555-565.	3.8	9
56	Animal Models in AIDS Research. , 2004, , 61-77.		0
57	Synthetic peptide-based reagents for blocking the entry and inactivation of HIV. , 2002, , 258-259.		0
58	Synthetic peptide-based HIV vaccine induces protective immunity in SHIV-rhesus model. , 2002, , 706-707.		0
59	Protection against chronic infection and AIDS by an HIV envelope peptide-cocktail vaccine in a pathogenic SHIV-rhesus model. Vaccine, 2001, 20, 813-825.	3.8	36
60	Impairment of antigen-specific cellular immune responses under simulated microgravity conditions. In Vitro Cellular and Developmental Biology - Animal, 2001, 37, 203-208.	1.5	16
61	Differences in functional immune responses of high vs. low hardy healthy individuals. Journal of Behavioral Medicine, 2001, 24, 219-229.	2.1	19
62	IMPAIRMENT OF ANTIGEN-SPECIFIC CELLULAR IMMUNE RESPONSES UNDER SIMULATED MICROGRAVITY CONDITIONS. In Vitro Cellular and Developmental Biology - Animal, 2001, 37, 203.	1.5	6
63	A comparison of cell-mediated immune responses in rhesus macaques housed singly, in pairs, or in groups. Applied Animal Behaviour Science, 2000, 68, 67-84.	1.9	71
64	Effects of dominance status and environmental enrichment on cell-mediated immunity in rhesus macaques. Applied Animal Behaviour Science, 1998, 56, 319-332.	1.9	23
65	Presence of HLA-C-Restricted Cytotoxic T-Lymphocyte Responses in Long-Term Nonprogressors Infected with Human Immunodeficiency Virus. Viral Immunology, 1998, 11, 119-129.	1.3	26
66	A Synthetic Peptide from the First Conserved Region in the Envelope Protein gp160 Is a Strong T-Cell Epitope in HIV-Infected Chimpanzees and Humans. Viral Immunology, 1998, 11, 147-158.	1.3	22
67	Cross-reactive T-cell proliferative responses to V3 peptides corresponding to different geographical HIV-1 isolates in HIV-seropositive individuals. Journal of Clinical Immunology, 1996, 16, 115-124.	3.8	7
68	Studies on V3-specific cross-reactive T-cell responses in chimpanzees chronically infected with HIV-1IIIB. Aids, 1995, 9, 567-572.	2.2	10
69	Cross-Reactive Cytotoxic T Lymphocytes Induced by V3 Loop Synthetic Peptides from Different Strains of Human Immunodeficiency Virus Type 1. Virology, 1995, 211, 261-267.	2.4	22
70	Studies on in vivo induction of HIV-1 envelope-specific cytotoxic T lymphocytes by synthetic peptides from the V3 loop region of HIV-1 IIIB gp120. Cellular Immunology, 1995, 160, 217-223.	3.0	28
71	Studies on in Vivo Induction of Cytotoxic T Lymphocyte Responses by Synthetic Peptides from E6 and E7 Oncoproteins of Human Papillomavirus Type 16. Viral Immunology, 1995, 8, 165-174.	1.3	30
72	Use of Helper T Cell-Inducing Peptides from Conserved Regions in HIV-1envin a Noncovalent Mixture with a CTL-Inducing V3-Loop Peptide forin VivoInduction of Long-Lasting Systemic CTL Response. Viral Immunology, 1994, 7, 189-197.	1.3	6

#	Article	IF	Citations
73	Induction of Human Immunodeficiency Virus-Specific T Cell Responses in Rhesus Monkeys by Synthetic Peptides from gp160. AIDS Research and Human Retroviruses, 1993, 9, 235-240.	1.1	15
74	Alternate Economical Starchy Substrates for the Production of 70% Sorbitol. Starch/Staerke, 1991, 43, 107-113.	2.1	7